ATE534752T1 - Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) - Google Patents

Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)

Info

Publication number
ATE534752T1
ATE534752T1 AT07872618T AT07872618T ATE534752T1 AT E534752 T1 ATE534752 T1 AT E534752T1 AT 07872618 T AT07872618 T AT 07872618T AT 07872618 T AT07872618 T AT 07872618T AT E534752 T1 ATE534752 T1 AT E534752T1
Authority
AT
Austria
Prior art keywords
mir
cll
lymphocytic leukemia
chronic lymphocytic
regulated
Prior art date
Application number
AT07872618T
Other languages
English (en)
Inventor
Carlo Croce
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE534752T1 publication Critical patent/ATE534752T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07872618T 2006-09-19 2007-09-17 Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) ATE534752T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84565706P 2006-09-19 2006-09-19
PCT/US2007/020215 WO2008097277A2 (en) 2006-09-19 2007-09-17 Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181

Publications (1)

Publication Number Publication Date
ATE534752T1 true ATE534752T1 (de) 2011-12-15

Family

ID=39682247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07872618T ATE534752T1 (de) 2006-09-19 2007-09-17 Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)

Country Status (9)

Country Link
US (1) US8071292B2 (de)
EP (1) EP2061907B1 (de)
JP (2) JP5426383B2 (de)
CN (1) CN101535505A (de)
AT (1) ATE534752T1 (de)
AU (1) AU2007346101B2 (de)
CA (1) CA2663027A1 (de)
ES (1) ES2374446T3 (de)
WO (1) WO2008097277A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533966B (zh) 2005-08-01 2014-03-12 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
EP2796554A3 (de) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Zusammensetzungen zur Behandlung von BCL2-assoziiertem Krebs
WO2007044413A2 (en) * 2005-10-05 2007-04-19 The Ohio State University Research Foundation Wwox gene, vectors containing the same, and uses in treatment of cancer
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CN103642900B (zh) 2006-01-05 2016-04-13 俄亥俄州立大学研究基金会 用于诊断和治疗实体癌的基于微小rna的方法和组合物
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
EP2455492B1 (de) 2006-07-13 2013-11-20 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
EP2061907B1 (de) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
EP2087135B8 (de) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Mikro-rna-expressionssignatur zur vorhersage des überlebens und von metastasen bei hepatozellulärem karzinom
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
EP2481806B1 (de) * 2007-04-30 2016-11-09 The Ohio State University Research Foundation Verfahren zur Prognosis von Bauchspeicheldrüsenkrebs
WO2008153987A2 (en) * 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
WO2009018303A2 (en) 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
ES2627059T3 (es) * 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
ES2562078T3 (es) * 2007-08-22 2016-03-02 The Ohio State University Research Foundation Métodos y composiciones para inducir la desregulación de la fosforilación de EphA7 y ERK en leucemias agudas humanas
WO2009049129A1 (en) * 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
AU2008329755A1 (en) * 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
US20110052502A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
CN104031984A (zh) * 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
KR20100064516A (ko) * 2008-12-05 2010-06-15 서울대학교산학협력단 마이크로rna를 유효성분으로 포함하는 항암제 및 그 제조방법
CA2781547A1 (en) 2009-11-23 2011-05-26 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
JP2013534824A (ja) * 2010-06-24 2013-09-09 ジ・オハイオ・ステート・ユニバーシティ 標的化されたmiR−29発現によりマウスにおいてモデル化された慢性リンパ性白血病
WO2012012676A2 (en) * 2010-07-22 2012-01-26 The University Of North Carolina At Chapel Hill Use of mir-29 for cell protection
WO2012065049A1 (en) 2010-11-12 2012-05-18 The Ohio State University Research Foundation Materials and methods related to microrna-21, mismatch repair, and colorectal cancer
AU2011329066B2 (en) 2010-11-15 2017-03-09 The Ohio State University Research Foundation Controlled release mucoadhesive systems
WO2012122239A1 (en) 2011-03-07 2012-09-13 The Ohio State University MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER
CN102329860B (zh) * 2011-08-24 2013-12-11 江涛 与替莫唑胺治疗胶质母细胞瘤相关的分子标志物
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
EP2804960A4 (de) 2012-01-20 2015-08-19 Univ Ohio State Brustkrebsbiomarkersignaturen für invasivität und prognose

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4608337A (en) * 1980-11-07 1986-08-26 The Wistar Institute Human hybridomas and the production of human monoclonal antibodies by human hybridomas
US4701409A (en) * 1984-11-15 1987-10-20 The Wistar Institute Detection of B-cell neoplasms
US4693975A (en) * 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
US5015568A (en) * 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) * 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US5198338A (en) * 1989-05-31 1993-03-30 Temple University Molecular probing for human t-cell leukemia and lymphoma
US5149628A (en) * 1989-11-15 1992-09-22 Temple University Methods for detecting bcl-3 gene in human leukemias
US5633135A (en) * 1991-12-11 1997-05-27 Thomas Jefferson University Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities
US6040140A (en) * 1991-12-11 2000-03-21 Thomas Jefferson University Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities
WO1993012136A1 (en) * 1991-12-11 1993-06-24 Thomas Jefferson University Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region
WO1994010343A1 (en) * 1992-10-29 1994-05-11 Thomas Jefferson University Methods of detecting micrometastasis of prostate cancer
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5985598A (en) * 1994-10-27 1999-11-16 Thomas Jefferson University TCL-1 gene and protein and related methods and compositions
US7175995B1 (en) * 1994-10-27 2007-02-13 Thomas Jefferson University TCL-1 protein and related methods
US5695944A (en) * 1995-05-05 1997-12-09 Thomas Jefferson University Modulation of bcl-2 phosphorylation
US5567586A (en) * 1995-05-18 1996-10-22 Thomas Jefferson University Methods of indentifying solid tumors with chromosome abnormalities in the ALL-1 region
US5928884A (en) * 1996-02-09 1999-07-27 Croce; Carlo M. FHIT proteins and nucleic acids and methods based thereon
US6242212B1 (en) * 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
US6187536B1 (en) 1997-02-18 2001-02-13 Thomas Jefferson University Methods of identifying and detecting pancreatic cancer
US6258541B1 (en) * 1997-04-04 2001-07-10 Texas A&M University Noninvasive detection of colonic biomarkers using fecal messenger RNA
EP1098968A4 (de) * 1998-07-20 2002-01-02 Univ Jefferson Homologe von nitrilase
US6255293B1 (en) * 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine
US7141417B1 (en) * 1999-02-25 2006-11-28 Thomas Jefferson University Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
JP2003519463A (ja) * 1999-03-15 2003-06-24 トーマス・ジェファーソン・ユニバーシティー TCL−1b遺伝子、蛋白質、それらに関連した方法およびそれらに関連する物質
US7163801B2 (en) 1999-09-01 2007-01-16 The Burnham Institute Methods for determining the prognosis for cancer patients using tucan
WO2001068666A1 (en) * 2000-03-14 2001-09-20 Thomas Jefferson University Tcl1 enhances akt kinase activity and mediates its nuclear translocation
US6924414B2 (en) * 2000-04-11 2005-08-02 Thomas Jefferson University Muir-torre-like syndrome in Fhit deficient mice
WO2001087958A2 (en) * 2000-05-16 2001-11-22 Thomas Jefferson University CRYSTAL STRUCTURE OF WORM NitFhit REVEALS THAT A Nit TETRAMER BINDS TWO Fhit DIMERS
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
IL161100A0 (en) * 2001-09-28 2004-08-31 Max Planck Gesellschaft Identification of novel genes coding for small temporal rnas
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
GB0128898D0 (en) * 2001-12-03 2002-01-23 Biotech Res Ventures Pte Ltd Materials and methods relating to the stabilization and activation of a tumour suppressor protein
CN104876904A (zh) 2002-03-08 2015-09-02 卫材R&D管理株式会社 用作医药品的大环化合物
AU2003226279A1 (en) * 2002-04-08 2003-10-27 Ciphergen Biosystems, Inc. Serum biomarkers in hepatocellular carcinoma
AU2003241325A1 (en) * 2002-04-29 2003-11-17 Thomas Jefferson University Human chronic lymphocytic leukemia modeled in mouse by targeted tcl1 expression
JP2005528115A (ja) * 2002-05-31 2005-09-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 幹細胞および癌幹細胞を同定および単離する方法
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
AU2003284083A1 (en) 2002-10-11 2004-05-04 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
US20050266443A1 (en) 2002-10-11 2005-12-01 Thomas Jefferson University Novel tumor suppressor gene and compositions and methods for making and using the same
CN102304570B (zh) 2002-11-13 2015-01-21 托马斯杰斐逊大学 用于癌症诊断和治疗的组合物和方法
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2004071464A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7183384B2 (en) * 2003-03-06 2007-02-27 A & G Pharmaceutical, Inc. Monoclonal antibody 7H11 reactive with human cancer
WO2004098377A2 (en) 2003-05-02 2004-11-18 Thomas Jefferson University Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
AU2004289953B2 (en) 2003-06-18 2008-09-25 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
WO2005047505A2 (en) * 2003-08-07 2005-05-26 Whitehead Institute For Biomedical Research Methods and products for expression of micro rnas
US20050037362A1 (en) * 2003-08-11 2005-02-17 Eppendorf Array Technologies, S.A. Detection and quantification of siRNA on microarrays
US8412541B2 (en) 2003-08-14 2013-04-02 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis for medical diagnosis
WO2005020795A2 (en) 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis
CA2539651A1 (en) 2003-09-22 2005-04-07 Rosetta Inpharmatics Llc Synthetic lethal screen using rna interference
US20070054849A1 (en) 2003-09-24 2007-03-08 Oncotherapy Science, Inc. Method for diagnosing hepatocellular carcinomas
US20050186589A1 (en) * 2003-11-07 2005-08-25 University Of Massachusetts Interspersed repetitive element RNAs as substrates, inhibitors and delivery vehicles for RNAi
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
US20050256072A1 (en) * 2004-02-09 2005-11-17 University Of Massachusetts Dual functional oligonucleotides for use in repressing mutant gene expression
EP2295604B1 (de) 2004-02-09 2015-04-08 Thomas Jefferson University Krebsdiagnose und Behandlung durch microRNA, die sich in der Nähe von Krebs-verbindenen Chromosom-Merkmale befinden
EP1723257B1 (de) 2004-02-23 2019-01-09 Erasmus University Medical Center Rotterdam Klassifizierung, diagnose und prognose von akuter myeolider leukämie über erstellung von genexpressionsprofilen
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
IL179285A (en) * 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
AU2005250432B2 (en) * 2004-05-28 2011-09-15 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
US20060037088A1 (en) * 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer
CA2583375C (en) 2004-09-02 2013-01-15 Yale University Regulation of oncogenes by micrornas
US7592441B2 (en) * 2004-10-04 2009-09-22 Rosetta Genomics Ltd Liver cancer-related nucleic acids
US7642348B2 (en) * 2004-10-04 2010-01-05 Rosetta Genomics Ltd Prostate cancer-related nucleic acids
FR2877350B1 (fr) 2004-11-03 2010-08-27 Centre Nat Rech Scient IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE
CA2857881A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
WO2008073922A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
CA2590768A1 (en) 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
EP1959012A3 (de) 2004-12-29 2009-12-30 Exiqon A/S Neuartige Oligonukleotid-Zusammensetzungen und Probensequenzen für die Erkennung und Analyse von Mikro-RNAs und ihre Ziel-MRNAs
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
ATE480644T1 (de) 2005-01-25 2010-09-15 Rosetta Inpharmatics Llc Verfahren zur quantifizierung kleiner rna- moleküle
US20070065840A1 (en) 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
GB2425311A (en) 2005-04-15 2006-10-25 Ist Superiore Sanita Micro RNA against kit protein
WO2006119266A2 (en) 2005-04-29 2006-11-09 Rockefeller University Human micrornas and methods for inhibiting same
EP1904111A4 (de) 2005-06-03 2009-08-19 Univ Johns Hopkins Zusammensetzungen und verfahren zur verringerung der microrna-expression zur behandlung von neoplasien
US20070065844A1 (en) 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
CN102533966B (zh) 2005-08-01 2014-03-12 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007021896A2 (en) 2005-08-10 2007-02-22 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
EP2796554A3 (de) * 2005-09-12 2014-12-10 The Ohio State University Research Foundation Zusammensetzungen zur Behandlung von BCL2-assoziiertem Krebs
WO2007044413A2 (en) 2005-10-05 2007-04-19 The Ohio State University Research Foundation Wwox gene, vectors containing the same, and uses in treatment of cancer
US7390792B2 (en) * 2005-12-15 2008-06-24 Board Of Regents, The University Of Texas System MicroRNA1 therapies
CN103642900B (zh) 2006-01-05 2016-04-13 俄亥俄州立大学研究基金会 用于诊断和治疗实体癌的基于微小rna的方法和组合物
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2007084486A2 (en) 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases
CN101448958A (zh) 2006-03-20 2009-06-03 俄亥俄州立大学研究基金会 人巨核细胞生成期间的微小rna指纹
US20090324618A1 (en) 2006-03-24 2009-12-31 Armstrong Scott A Novel signature self renewal gene expression programs
CN101472470B (zh) * 2006-04-24 2013-07-24 俄亥俄州立大学研究基金会 miR155转基因小鼠中前B细胞增殖和淋巴母细胞性白血病/高度淋巴瘤
EP2455492B1 (de) 2006-07-13 2013-11-20 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
US20080193943A1 (en) 2006-09-05 2008-08-14 Abbott Laboratories Companion diagnostic assays for cancer therapy
CA2663878A1 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
EP2061907B1 (de) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
WO2008036776A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2087135B8 (de) 2006-11-01 2013-07-24 The Ohio State University Research Foundation Mikro-rna-expressionssignatur zur vorhersage des überlebens und von metastasen bei hepatozellulärem karzinom
US8293684B2 (en) 2006-11-29 2012-10-23 Exiqon Locked nucleic acid reagents for labelling nucleic acids
WO2008070082A2 (en) 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2008073920A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101622349A (zh) 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-21调节的基因和途径
AU2007333106A1 (en) 2006-12-08 2008-06-19 Asuragen, Inc. miR-20 regulated genes and pathways as targets for therapeutic intervention
US20090175827A1 (en) 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
CN101688240A (zh) 2007-04-10 2010-03-31 国立台湾大学 通过微rna预测癌症患者的治疗后存活预期
EP2481806B1 (de) 2007-04-30 2016-11-09 The Ohio State University Research Foundation Verfahren zur Prognosis von Bauchspeicheldrüsenkrebs
US20090005336A1 (en) 2007-05-08 2009-01-01 Zhiguo Wang Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions
US20090131354A1 (en) 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
JP2010529966A (ja) 2007-06-08 2010-09-02 アシュラジェン インコーポレイテッド 治療的介入の標的としてmiR−34によって調節される遺伝子および経路
WO2008153987A2 (en) 2007-06-08 2008-12-18 The Government Of The United States Of America As Represented By The Secretary Of Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
AU2008266014B2 (en) 2007-06-15 2013-06-06 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting drosha-mediated microRNA processing
WO2009018303A2 (en) 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
ES2562078T3 (es) 2007-08-22 2016-03-02 The Ohio State University Research Foundation Métodos y composiciones para inducir la desregulación de la fosforilación de EphA7 y ERK en leucemias agudas humanas
US20090061424A1 (en) 2007-08-30 2009-03-05 Sigma-Aldrich Company Universal ligation array for analyzing gene expression or genomic variations
EP2775001B1 (de) 2007-09-06 2016-03-09 The Ohio State University Research Foundation MikroRNA-Signaturen in menschlichem Ovarialkarzinom
WO2009049129A1 (en) 2007-10-11 2009-04-16 The Ohio State University Research Foundation Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas
WO2009055773A2 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
US20090123933A1 (en) 2007-11-12 2009-05-14 Wake Forest University Health Sciences Microrna biomarkers in lupus
US8575121B2 (en) 2007-11-12 2013-11-05 The United States of America as represented by the Secetary of the Department of Health and Human Services Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
AU2008329755A1 (en) 2007-11-30 2009-06-04 The Ohio State University Research Foundation MicroRNA expression profiling and targeting in peripheral blood in lung cancer
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
ES2936256T3 (es) 2008-02-01 2023-03-15 Massachusetts Gen Hospital Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas
US20090263803A1 (en) 2008-02-08 2009-10-22 Sylvie Beaudenon Mirnas differentially expressed in lymph nodes from cancer patients
US20110052502A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof
WO2009108853A1 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation MicroRNA-BASED METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF GASTRIC CANCER
EP2250496A4 (de) 2008-02-28 2011-08-31 Univ Ohio State Res Found Mit zytogenetik und prognose assoziierte microrna-signaturen bei akuter myeloischer leukämie (aml) und ihre verwendung
CN104031984A (zh) 2008-02-28 2014-09-10 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
WO2009154835A2 (en) 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
EP2990487A1 (de) 2008-05-08 2016-03-02 Asuragen, INC. Zusammensetzungen und verfahren in zusammenhang mit der mirna-modulation von neovaskularisation oder angiogenese
EP2306978A2 (de) 2008-06-06 2011-04-13 Mirna Therapeutics, Inc. Zusammensetzungen zur abgabe von rnai-mitteln in vivo
WO2009152300A1 (en) 2008-06-11 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010019694A1 (en) 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
WO2010059779A1 (en) 2008-11-21 2010-05-27 The Ohio State University Research Foundation Tcl1 AS A TRANSCRIPTIONAL REGULATOR
US20110275534A1 (en) 2008-12-05 2011-11-10 The Ohio State University MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform
CA2753562A1 (en) 2009-02-26 2010-09-02 The Ohio State University Research Foundation Micrornas in never-smokers and related materials and methods

Also Published As

Publication number Publication date
US20100004322A1 (en) 2010-01-07
AU2007346101B2 (en) 2013-08-15
US8071292B2 (en) 2011-12-06
JP2010503420A (ja) 2010-02-04
WO2008097277A3 (en) 2008-10-09
EP2061907A4 (de) 2010-08-04
AU2007346101A1 (en) 2008-08-14
CA2663027A1 (en) 2008-08-14
ES2374446T3 (es) 2012-02-16
CN101535505A (zh) 2009-09-16
EP2061907A2 (de) 2009-05-27
WO2008097277A2 (en) 2008-08-14
JP5426383B2 (ja) 2014-02-26
EP2061907B1 (de) 2011-11-23
JP2014113146A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
PH12018500045A1 (en) Compositions and methods for treating and diagnosing asthma
CY1122278T1 (el) Αντι il-36r αντισωματα
EP2569434A4 (de) Zusammensetzungen und verfahren zur behandlung von leukämie
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201071421A1 (ru) Анти-flt3 антитела
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
SG179038A1 (en) Compositions and methods for diagnosing autism spectrum disorders
MY153198A (en) Inhibitors of protein aggregation
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
EP2331093A4 (de) Verbindungen, zusammensetzungen und verfahren zur toxizitätsverringerung und behandlung bzw. vorbeugung von erkrankungen
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
EA200701995A1 (ru) Способы уменьшения кальцификации
MX2009005400A (es) Metodo para el diagnostico y tratamiento del glioma.
WO2010054221A3 (en) Treatment of chronic inflammatory respiratory disorders